Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus

Alemtuzumab is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting multiple sclerosis with active disease. Multiple sclerosis (MS) patients treated with alemtuzumab are at increased risk for autoimmune adverse events (thyroid disorders, immune throm...

Descripción completa

Detalles Bibliográficos
Autores principales: Sprangers, Ben, Decoo, D., Dive, D., Lysandropoulos, A., Vanopdenbosch, L., Bovy, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Consensus paper and Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971040/
https://www.ncbi.nlm.nih.gov/pubmed/29189966
http://dx.doi.org/10.1007/s13760-017-0864-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971040/
https://www.ncbi.nlm.nih.gov/pubmed/29189966
http://dx.doi.org/10.1007/s13760-017-0864-x

Ejemplares similares